Combined Biologic and Surgical Interventions for Hidradenitis Suppurativa: A Systematic Review

Table 2

Patient demographics.

Authors	Cohort	No. of patients	Average age (years ± SD)	Female (no. of patients, %)	Average BMI (kg/m^2)	Surgical site Hurley stage (no. of patients, %)
Adalimumab
Aarts et al. [9]	CTC	31	40.2 ± 11.7	17 (55%)	29.5 ± 6.6	I	1 (3%)
						II	22 (71%)
						III	8 (26%)
	BOC	31	37.5 ± 12.7	17 (55%)	30.2 ± 6.1	I	1 (3%)
						II	22 (71%)
						III	8 (26%)
Bechara et al. [10]	CTC	103	38.5 ± 11.7	51 (49.5%)	32.6	II	53 (51%)
						III	50 (48%)
	PSC	103	36.8 ± 10.8	55 (53%)	31.7	II	54 (52%)
						III	49 (47%)
Adalimumab, infliximab
Prens et al. [12]	CTC	5	41.0 ± 10.8	4 (80%)	31.3	IIB^a	2 (40%)
						III^a	3 (60%)
	SOC	34	39.3	30 (88%)	28.7	IA/B^a	2 (6%)/2 (6%)
						IIA/B/C^a	6 (18%)/19 (56%)/4 (12%)
						III^a	1 (3%)
Worden et al. [16]	CTC	248	45.0 ± 17	186 (75%)	26	Hurley stage sites affected (no. of sites, %)
						I	131 (17%)
	SOC					II	442 (56%)
						III	210 (27%)
Adalimumab, infliximab, ustekinumab
Salvador-Rodriguez et al. [13]	CTC	21	40.6 ± 15.2	9 (43%)	31.5	II	12 (57%)
						III	9 (43%)
	SOC	38	35.6 ± 9.9	27 (71%)	30.8	II	33 (87%)
						III	5 (13%)
Shanmugam et al. [14]	CTC; BOC; SOC	68	40.4 ± 14	45 (66%)	34	0	2 (3%)
						I	6 (9%)
						II	13 (19%)
						III	43 (63%)
						Unspecified	4 (6%)
Infliximab, ustekinumab
DeFazio et al. [11]	CTC	11	31	7 (64%)	36	III	11 (100%)
	SOC	10	33	7 (70%)	35.5		10 (100%)
Infliximab
Van Rappard and Mekkes [15]	CTC	24	44^b	13 (43%)	Not reported	II	4 (13%)
	BOC	6				III	26 (87%)

^aRefined Dutch Hurley Stage Classification 2017. ^bRange given was age 19 to 63. %, percent; ±, plus or minus; BMI, body mass index (calculated as weight in kilograms divided by height in meters); BOC, biologic-only cohort (patients treated with only biologic therapy); CTC, combined treatment cohort (patients receiving biologic and surgical therapy); kg/m², kilogram per meter squared; No., number; PSC, placebo and surgical cohort; SD, standard deviation; SOC, surgery-only cohort.